These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29197875)

  • 41. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
    Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Leuprorelin: a leading role in advanced prostate cancer therapy.
    Persad R
    Hosp Med; 2003 Jun; 64(6):360-3. PubMed ID: 12833832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.
    Tunn UW; Gruca D; Bacher P
    Clin Interv Aging; 2013; 8():457-64. PubMed ID: 23637525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis.
    Hammerer PG; Wirth MP;
    Urol Int; 2018; 100(1):72-78. PubMed ID: 29183006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations.
    Merseburger AS; Björk T; Whitehouse J; Meani D
    J Comp Eff Res; 2015 Sep; 4(5):447-53. PubMed ID: 25521079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effectiveness and tolerance of three month sustained release leuprorelin in the treatment of metastatic prostatic cancer (comparative, randomized, multicentric study].
    Zerbib M; Lucas C; Leblanc V
    Prog Urol; 1997 Apr; 7(2):246-53. PubMed ID: 9264767
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
    Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
    J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
    [No Abstract]   [Full Text] [Related]  

  • 49. Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate.
    Park S; Kim DH; Kim Y; Park JH; Lee M; Song IS; Shim CK
    Drug Dev Ind Pharm; 2017 Mar; 43(3):441-447. PubMed ID: 27824264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
    Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
    Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
    Lim CN; Salem AH
    Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. What should I know about Lupron Depot for treating prostate cancer?
    Johns Hopkins Med Lett Health After 50; 2012 Jan; 23(11):7. PubMed ID: 22396997
    [No Abstract]   [Full Text] [Related]  

  • 53. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical pharmacokinetics of depot leuprorelin.
    Periti P; Mazzei T; Mini E
    Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Life-threatening anaphylaxis to leuprorelin acetate depot: case report and review of the literature.
    Fujisaki A; Kondo Y; Goto K; Morita T
    Int J Urol; 2012 Jan; 19(1):81-4. PubMed ID: 22050405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quality of life improvement in patients treated with degarelix versus leuprorelin for advanced prostate cancer.
    Lee D; Nielsen SK; van Keep M; Andersson F; Greene D
    J Urol; 2015 Mar; 193(3):839-46. PubMed ID: 25264336
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group.
    Fernandez del Moral P; Dijkman GA; Debruyne FM; Witjes WP; Kolvenbag GJ
    Urology; 1996 Dec; 48(6):894-900. PubMed ID: 8973673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer.
    Perez-Marrero R; Tyler RC
    Expert Opin Pharmacother; 2004 Feb; 5(2):447-57. PubMed ID: 14996640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anaphylaxis to leuprolide acetate depot injection during treatment for prostate cancer.
    Grant JP; Levinson AW
    Clin Genitourin Cancer; 2007 Mar; 5(4):284-6. PubMed ID: 17553209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.